RxDoctor Payments Data

Kristoffer Arellano

Family · Pennington, NJNPI 1902346455

Payments from drug & device makers

$2,952in general payments, 2019–2025

Across 101 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$877
  • AstraZeneca$456
  • Alnylam Pharmaceuticals Inc.$368
  • Actelion Pharmaceuticals US, Inc.$294
  • United Therapeutics Corporation$147
  • Pfizer$114
  • plus $695 from 17 others

What the payments were for

  • Food & beverage$2,23576%
  • Education$71724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,952 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$4,083
Medicare patients
44
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan61$851,306
UptraviSelexipag22$509,303
EntrestoSacubitril/Valsartan393$405,142
FarxigaDapagliflozin Propanediol281$267,725
VyndamaxTafamidis12$260,415
CamzyosMavacamten18$133,842
EliquisApixaban98$91,004
JardianceEmpagliflozin57$54,118
Sildenafil Citrate70$40,312
XareltoRivaroxaban20$19,030
BrilintaTicagrelor22$15,507
Bumetanide217$6,583
CorlanorIvabradine Hcl11$5,916
Metoprolol Succinate255$3,374
Potassium Chloride107$3,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$294$1,360,60983 claims
PfizerVyndamax, Eliquis$114$351,419110 claims
AstraZenecaFarxiga, Brilinta$456$283,232303 claims
E.r. Squibb & Sons, L.L.C.Camzyos$44$133,84218 claims
Boehringer IngelheimJardiance$54$54,11857 claims
Johnson & JohnsonXarelto$60$19,03020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Pennington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →